Cisplatin



Combined with:

Indications and Reactions:

Role Indications Reactions
Primary
Non-small Cell Lung Cancer 21.9%
Gastric Cancer 14.6%
Prophylaxis 8.0%
Pain 4.6%
Hypertension 4.6%
Gastrooesophageal Cancer 4.4%
Nausea 4.1%
Testis Cancer 4.0%
Oesophageal Carcinoma 3.7%
Head And Neck Cancer 3.6%
Squamous Cell Carcinoma 3.5%
Small Cell Lung Cancer Stage Unspecified 3.3%
Germ Cell Cancer 3.0%
Metastatic Gastric Cancer 2.9%
Lung Neoplasm Malignant 2.6%
Constipation 2.4%
Neoplasm Malignant 2.3%
Non-small Cell Lung Cancer Stage Iii 2.3%
Prophylaxis Of Nausea And Vomiting 2.1%
Premedication 2.0%
Vomiting 21.0%
White Blood Cell Count Decreased 7.6%
Thrombocytopenia 6.7%
Pulmonary Embolism 6.6%
Renal Failure Acute 6.2%
Neutropenia 5.5%
Pyrexia 5.3%
Weight Decreased 4.9%
Sepsis 4.2%
Stomatitis 3.6%
Febrile Neutropenia 3.5%
Nausea 3.5%
Renal Failure 3.5%
Dehydration 3.3%
Mucosal Inflammation 2.8%
Pneumonia 2.7%
Syncope 2.5%
Urinary Tract Infection 2.4%
Neutrophil Count Decreased 2.3%
Deep Vein Thrombosis 2.0%
Secondary
Non-small Cell Lung Cancer 19.9%
Prophylaxis 11.9%
Gastric Cancer 9.7%
Head And Neck Cancer 9.5%
Multiple Myeloma 6.5%
Drug Use For Unknown Indication 6.1%
Product Used For Unknown Indication 3.5%
Oesophageal Carcinoma 3.4%
Gastrooesophageal Cancer 3.3%
Squamous Cell Carcinoma 3.3%
Hypertension 3.2%
Pain 3.2%
Nausea 2.8%
Bone Sarcoma 2.7%
Non-hodgkin's Lymphoma 1.9%
Lung Neoplasm Malignant 1.9%
Metastatic Gastric Cancer 1.9%
Prophylaxis Of Nausea And Vomiting 1.8%
Premedication 1.8%
Mantle Cell Lymphoma 1.7%
Vomiting 14.7%
Thrombocytopenia 8.9%
Pulmonary Embolism 7.6%
Neutropenia 6.8%
White Blood Cell Count Decreased 6.0%
Sepsis 5.2%
Death 4.9%
Pneumonia 4.8%
Febrile Neutropenia 4.8%
Pyrexia 4.6%
Weight Decreased 4.0%
Renal Failure 3.9%
Renal Failure Acute 3.9%
Off Label Use 3.8%
Stomatitis 3.0%
Mucosal Inflammation 3.0%
Septic Shock 2.6%
General Physical Health Deterioration 2.6%
Nausea 2.5%
Dyspnoea 2.4%
Concomitant
Drug Use For Unknown Indication 15.9%
Product Used For Unknown Indication 12.4%
Non-small Cell Lung Cancer 11.6%
Chemotherapy 6.8%
Prophylaxis 6.5%
Prophylaxis Of Nausea And Vomiting 5.6%
Lung Adenocarcinoma 5.3%
Premedication 3.9%
Lung Neoplasm Malignant 3.9%
Gastric Cancer 3.8%
Diffuse Large B-cell Lymphoma 3.2%
Squamous Cell Carcinoma 2.7%
Multiple Myeloma 2.7%
Lung Adenocarcinoma Stage Iv 2.7%
Hypertension 2.5%
Pain 2.3%
Transitional Cell Carcinoma 2.2%
Head And Neck Cancer 2.1%
Metastases To Bone 2.0%
Metastatic Gastric Cancer 2.0%
Vomiting 15.2%
Thrombocytopenia 10.7%
White Blood Cell Count Decreased 8.5%
Death 7.5%
Pyrexia 6.1%
Pulmonary Embolism 5.5%
Neutropenia 4.9%
Sepsis 4.8%
Weight Decreased 3.9%
Febrile Neutropenia 3.6%
Nausea 3.6%
Renal Failure Acute 3.6%
Renal Failure 3.4%
Pneumonia 3.1%
Interstitial Lung Disease 2.8%
Diarrhoea 2.6%
Pancytopenia 2.6%
Platelet Count Decreased 2.6%
Respiratory Failure 2.6%
Myocardial Infarction 2.5%
Interacting
Chemotherapy 12.9%
Bile Duct Cancer 11.0%
Glioblastoma Multiforme 11.0%
Product Used For Unknown Indication 9.2%
Malignant Hydatidiform Mole 6.1%
Gastric Cancer 5.5%
General Anaesthesia 5.5%
Bone Sarcoma 3.7%
Essential Thrombocythaemia 3.7%
Hiv Infection 3.7%
Lung Carcinoma Cell Type Unspecified Stage Iv 3.7%
Lung Neoplasm Malignant 3.7%
Mantle Cell Lymphoma 3.7%
Gestational Trophoblastic Tumour 3.1%
Urethral Cancer 3.1%
Status Epilepticus 2.5%
Urinary Tract Infection 2.5%
Mental Disorder 1.8%
Pain 1.8%
Squamous Cell Carcinoma 1.8%
Pyrexia 15.8%
Pancytopenia 10.5%
Drug Interaction 7.9%
Diarrhoea 5.3%
Hallucination, Visual 5.3%
Muscle Haemorrhage 5.3%
Ophthalmoplegia 5.3%
Paralysis 5.3%
Renal Impairment 5.3%
Reversible Posterior Leukoencephalopathy Syndrome 5.3%
Vomiting 5.3%
Cholangitis Sclerosing 2.6%
Haematotoxicity 2.6%
International Normalised Ratio Increased 2.6%
Malnutrition 2.6%
Mucosal Inflammation 2.6%
Off Label Use 2.6%
Platelet Count Decreased 2.6%
Pneumatosis Intestinalis 2.6%
Renal Failure Acute 2.6%